Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a currative treatment modality for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available regarding which patients with relapsed or refractory DLBCL are l...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2024-03, Vol.59 (3), p.306-314
Main Authors: Kato, Koji, Sugio, Takeshi, Ikeda, Takashi, Yoshitsugu, Kanako, Miyazaki, Kana, Suzumiya, Junji, Yamamoto, Go, Kim, Sung-Won, Ikegame, Kazuhiro, Uehara, Yasufumi, Mori, Yasuo, Ishikawa, Jun, Hiramoto, Nobuhiro, Eto, Tetsuya, Nakazawa, Hideyuki, Kobayashi, Hikaru, Serizawa, Kentaro, Onizuka, Makoto, Fukuda, Takahiro, Atsuta, Yoshiko, Suzuki, Ritsuro
Format: Article
Language:English
Subjects:
692/699
692/699/1541/1990/291/1621/1915
Allografts
B-cell lymphoma
Cell Biology
Cell therapy
Chimeric antigen receptors
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Immunotherapy
Internal Medicine
Lymphocytes B
Lymphocytes T
Lymphoma
Lymphoma, Large B-Cell, Diffuse - therapy
Lymphoma, Non-Hodgkin
Male
Medical prognosis
Medicine
Medicine & Public Health
Multivariate analysis
Neoplasm Recurrence, Local - therapy
Public Health
Recurrence
Retrospective Studies
Stem cell transplantation
Stem Cells
Subgroups
Survival
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a currative treatment modality for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available regarding which patients with relapsed or refractory DLBCL are likely to benefit from allo-HSCT. We retrospectively analyzed data from 1268 DLBCL patients who received allo-HSCT. The overall survival and progression-free survival (PFS) rates were 30.3% and 21.6% at 3 years, respectively. Multivariate analysis revealed that stable or progressive disease at transplantation, male patient, poorer performance status at transplantation, and shorter intervals from previous transplantation were associated independently with a lower PFS. Four prognostic factors were used to construct a prognostic index for PFS, predicting 3-year PFS of 55.4%, 43.7%, 20.4% and 6.6%, respectively. The prognostic model predicted relapse rates following allo-HSCT accordingly ( P  
ISSN:0268-3369
1476-5365
1476-5365
DOI:10.1038/s41409-023-02156-4